GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ampio Pharmaceuticals Inc (OTCPK:AMPE) » Definitions » 3-Year ROIIC %

AMPE (Ampio Pharmaceuticals) 3-Year ROIIC % : -143.71% (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Ampio Pharmaceuticals 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Ampio Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2023 was -143.71%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Ampio Pharmaceuticals's 3-Year ROIIC % or its related term are showing as below:

AMPE's 3-Year ROIIC % is ranked worse than
73.86% of 1358 companies
in the Biotechnology industry
Industry Median: -13.43 vs AMPE: -143.71

Ampio Pharmaceuticals 3-Year ROIIC % Historical Data

The historical data trend for Ampio Pharmaceuticals's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ampio Pharmaceuticals 3-Year ROIIC % Chart

Ampio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
3-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.23 4.80 433.58 33.82 -143.71

Ampio Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.82 - - - -143.71

Competitive Comparison of Ampio Pharmaceuticals's 3-Year ROIIC %

For the Biotechnology subindustry, Ampio Pharmaceuticals's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ampio Pharmaceuticals's 3-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ampio Pharmaceuticals's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Ampio Pharmaceuticals's 3-Year ROIIC % falls into.



Ampio Pharmaceuticals 3-Year ROIIC % Calculation

Ampio Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -9.518 (Dec. 2023) - -15.834 (Dec. 2020) )/( 0.274 (Dec. 2023) - 4.669 (Dec. 2020) )
=6.316/-4.395
=-143.71%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Ampio Pharmaceuticals  (OTCPK:AMPE) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Ampio Pharmaceuticals 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Ampio Pharmaceuticals's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ampio Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
9800 Mount Pyramid Court, Suite 400, Englewood, CO, USA, 80112
Ampio Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development of a potential treatment for osteoarthritis of the knee ("OAK") as part of its OA-201 development program ("OA-201 program" or "OA-201").
Executives
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Michael A Martino director C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
David R Stevens director 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Elizabeth Varki Jobes director 640 LEE ROAD, CHESTERBROOK PA 19087
Philip H Coelho director C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Holli Cherevka officer: Chief Operating Officer C/O AMPIO PHARMACEUTICALS, INC., 373 IVERNESS PARKWAY, ENGLEWOOD CO 80112
Dan Stokely officer: CFO 4810 EASTGATE MALL, SAN DIEGO CA 92121
Chilcott, Iii Thomas E. officer: Chief Financial Officer 373 INVERNESS PARKWAY, ENGLEWOOD CO 80122
Gregory A Gould officer: Chief Financial Officer 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Joshua R. Disbrow officer: Chief Operating Officer AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Michael Macaluso director C/O AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Richard B Giles director 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
David Bar-or director, officer: Chief Scientific Officer C/O AMPIO PHARMACEUTICALS, INC., 373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD CO 80112
Vaughan Lennox Clift officer: Chief Regulatory Affairs 807 NOBLE SPRINGS ROAD, HOUSTON TX 77062
Mark D Mcgregor officer: Chief Financial Officer 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111